Thomas Stauffer Larsen
Overview
Explore the profile of Thomas Stauffer Larsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1057
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vimalathas G, Cedile O, Kjeldsen M, Thomassen M, Moller M, Nyvold C, et al.
Int J Lab Hematol
. 2025 Feb;
PMID: 40013464
Introduction: Formalin-fixed paraffin-embedded (FFPE) tumor biopsy is the current mainstay of genotyping, but is limited by its invasiveness and tumor heterogeneity. Plasma cell-free DNA (cfDNA) constitutes a minimally invasive alternative...
2.
Weisbjerg D, Skarphedinsson S, Andersen N, Kristensen L, Larsen T, Knudtzen F
Case Rep Oncol
. 2025 Feb;
18(1):213-219.
PMID: 39980502
Introduction: Lyme borreliosis has been associated with lymphoma, particularly cutaneous lymphomas. The literature is conflicted regarding the effect of antibiotic therapy in cutaneous marginal zone lymphomas (MZLs) in individuals with...
3.
Pedersen L, Klausen N, Jensen J, Bacevicius E, Brown P, Jorgensen J, et al.
EJHaem
. 2025 Jan;
6(1):e1070.
PMID: 39866948
Background: There is limited knowledge of the long-term effects on the immune system after treatment for diffuse large B-cell lymphoma (DLBCL). Methods: This study included DLBCL patients from the Danish...
4.
Kyvsgaard E, Grauslund M, Sjo L, Melchior L, Grantzau T, Gjerdrum L, et al.
Am J Hematol
. 2025 Jan;
100(4):712-716.
PMID: 39865309
No abstract available.
5.
Bennedsen T, Simonsen M, Jensen P, Brown P, Josefsson P, Khurana A, et al.
Eur J Haematol
. 2025 Jan;
PMID: 39786332
The development of new first-line treatments for patients with follicular lymphoma (FL) is becoming increasingly challenging due to already excellent survival outcomes. The present study investigated the outcomes of patients...
6.
Jelicic J, Juul-Jensen K, Bukumiric Z, Simonsen M, Kragh Jorgensen R, Clausen M, et al.
Ann Hematol
. 2024 Dec;
104(1):433-444.
PMID: 39738862
The International Prognostic Index (IPI) is the most frequently used tool for prognostication in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) of all ages. This study validated and...
7.
Simonsen M, Jensen J, Larsen T, Gade I, de Nully Brown P, El-Galaly T
Eur J Haematol
. 2024 Dec;
114(3):528-535.
PMID: 39638554
Objectives: Accurate prevalence estimates of diffuse large B-cell lymphoma (DLBCL) are important for numerous purposes including orphan drug designation. A key criterion for orphan drug designation is a disease prevalence...
8.
Vimalathas G, Lang C, Green T, Moller M, Nyvold C, Hansen M, et al.
Eur J Haematol
. 2024 Nov;
114(3):469-480.
PMID: 39565012
Introduction: Diffuse large B-cell lymphoma (DLBCL) exhibits striking clinical and biological heterogeneity. Recent studies have identified new subgroups within germinal center B-cell like (GCB) DLBCL, associated with inferior prognosis, irrespective...
9.
Jelicic J, Juul-Jensen K, Bukumiric Z, Simonsen M, Clausen M, Al-Mashhadi A, et al.
Eur J Haematol
. 2024 Sep;
114(1):26-36.
PMID: 39257078
Objectives: Recent front-line clinical trials used the International Prognostic Index (IPI) to identify trial-eligible patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, many IPI-like variants with improved accuracy...
10.
Simonsen M, Haunstrup L, Severinsen F, Jensen R, de Nully Brown P, Maurer M, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2173-2181.
PMID: 39225407
Up to 50% of diffuse large B-cell lymphoma (DLBCL) patients are ineligible for participation in clinical trials. Ineligible patients have inferior outcomes, but less is known about the impact of...